Aptinyx Investor Relations Material
Latest events
Q3 2022
Aptinyx
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aptinyx Inc
Access all reports
Aptinyx Inc. is a biopharmaceutical company focused on developing therapies for neurological disorders. The company leverages its expertise in small-molecule compounds that modulate NMDA receptors to address conditions such as chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx’s research and development efforts aim to create innovative treatments for patients with unmet medical needs. The company is headquartered in Evanston, Illinois, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
APTX
Country
🇺🇸 United States